Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1978 Jun;91(3):517–530.

Phospholipase A2 contamination of cobra venom factor preparations. Biologic role in complement-dependent in vivo reactions and inactivation with p-bromophenacyl bromide.

J O Shaw, M F Roberts, R J Ulevitch, P Henson, E A Dennis
PMCID: PMC2018306  PMID: 655262

Abstract

Cobra venom factor (CoF), the anticomplementary protein in Naja naja cobra venom, is usually purified by sequential ion exchange and gel filtration chromatography. CoF prepared in this manner contains small but significant quantities of phospholipase A2 activity. This acyl hydrolase activity can be simply and efficiently removed on a large scale by treatment of CoF with p-bromophenacyl bromide (BPB), an irreversible modifier of the histidine residue in the active site of phospholipase A2. BPB treatment does not alter the anticomplementary activity of CoF. In vivo experiments utilizing intratracheal injections of control and BPB-treated CoF, as well as pure phospholipase A2, revealed that contaminating phospholipase A2, and not the anticomplementary protein, was responsible for the observed acute neutrophil-associated lung injury. However, phospholipase A2 had no effect on the hypotensive and thrombocytopenic effects of CoF infected intravenously into rabbits. Depletion of circulating C3-C9 by intraperitoneal injections of CoF was not altered by removal of phospholipase A2 activity with BPB.

Full text

PDF
517

Images in this article

529Figure 1
on p.529
529Figure 2
on p.529
530Figure 3
on p.530
530Figure 4
on p.530

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballow M., Cochrane C. G. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J Immunol. 1969 Nov;103(5):944–952. [PubMed] [Google Scholar]
  2. Cochrane C. G., Müller-Eberhard H. J., Aikin B. S. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol. 1970 Jul;105(1):55–69. [PubMed] [Google Scholar]
  3. Cooper N. R. Formation and function of a complex of the C3 proactivator with a protein from cobra venom. J Exp Med. 1973 Feb 1;137(2):451–460. doi: 10.1084/jem.137.2.451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Deems R. A., Dennis E. A. Characterization and physical properties of the major form of phospholipase A2 from cobra venom (Naja naja naja) that has a molecular weight of 11,000. J Biol Chem. 1975 Dec 10;250(23):9008–9012. [PubMed] [Google Scholar]
  5. Dennis E. A. Kinetic dependence of phospholipase A 2 activity on the detergent Triton X-100. J Lipid Res. 1973 Mar;14(2):152–159. [PubMed] [Google Scholar]
  6. Dierich M. P., Hadding U., König W., Limbert M., Schorlemmer H. U., Bitter-Suermann D. Factor D in the alternate pathway of complement activation: purification, physicochemical characterization and functional role. Immunochemistry. 1974 Sep;11(9):527–532. doi: 10.1016/0019-2791(74)90242-0. [DOI] [PubMed] [Google Scholar]
  7. FERRARI A. Nitrogen determination by a continuous digestion and analysis system. Ann N Y Acad Sci. 1960 Jul 22;87:792–800. doi: 10.1111/j.1749-6632.1960.tb23236.x. [DOI] [PubMed] [Google Scholar]
  8. Hall J. L., Rowlands D. T., Jr, Nilsson U. R. Complement-unlike hemolytic activity in lobster hemolymph. J Immunol. 1972 Oct;109(4):816–823. [PubMed] [Google Scholar]
  9. Henson P. M., Cochrane C. G. The effect of complement depletion on experimental tissue injury. Ann N Y Acad Sci. 1975 Jun 13;256:426–440. doi: 10.1111/j.1749-6632.1975.tb36069.x. [DOI] [PubMed] [Google Scholar]
  10. Lachmann P. J., Halbwachs L., Gewurz A., Gewurz H. Purification of cobra venom factor from phospholipase A contaminant. Immunology. 1976 Dec;31(6):961–968. [PMC free article] [PubMed] [Google Scholar]
  11. McCall C. E., De Chatelet L. R., Brown D., Lachmann P. New biological activity following intravascular activation of the complement cascade. Nature. 1974 Jun 28;249(460):841–843. doi: 10.1038/249841a0. [DOI] [PubMed] [Google Scholar]
  12. Müller-Eberhard H. J., Fjellström K. E. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol. 1971 Dec;107(6):1666–1672. [PubMed] [Google Scholar]
  13. Pepys M. B. Role of complement in the induction of immunological responses. Transplant Rev. 1976;32:93–120. doi: 10.1111/j.1600-065x.1976.tb00230.x. [DOI] [PubMed] [Google Scholar]
  14. Roberts M. F., Deems R. A., Dennis E. A. Dual role of interfacial phospholipid in phospholipase A2 catalysis. Proc Natl Acad Sci U S A. 1977 May;74(5):1950–1954. doi: 10.1073/pnas.74.5.1950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Roberts M. F., Deems R. A., Dennis E. A. Spectral perturbations of the histidine and tryptophan in cobra venom phospholipase A2 upon metal ion and mixed micelle binding. J Biol Chem. 1977 Sep 10;252(17):6011–6017. [PubMed] [Google Scholar]
  16. Roberts M. F., Deems R. A., Mincey T. C., Dennis E. A. Chemical modification of the histidine residue in phospholipase A2 (Naja naja naja). A case of half-site reactivity. J Biol Chem. 1977 Apr 10;252(7):2405–2411. [PubMed] [Google Scholar]
  17. Ruddy S., Austen K. F., Goetzl E. J. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B. J Clin Invest. 1975 Mar;55(3):587–592. doi: 10.1172/JCI107966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ulevitch R. J., Cochrane C. G. Complement-dependent hemodynamic and hematologic changes in the rabbit. Inflammation. 1977 Sep;2(3):199–216. doi: 10.1007/BF00917596. [DOI] [PubMed] [Google Scholar]
  19. Ulevitch R. J., Cochrane C. G., Henson P. M., Morrison D. C., Doe W. F. Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement. J Exp Med. 1975 Dec 1;142(6):1570–1590. doi: 10.1084/jem.142.6.1570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Vincent J. E., Zijlstra F. J. Biphasic effects of phospholipase A2 on platelet aggregation. Effect of prostaglandin synthesis inhibitors and essential fatty acid deficiency. Prostaglandins. 1976 Dec;12(6):971–979. doi: 10.1016/0090-6980(76)90130-1. [DOI] [PubMed] [Google Scholar]
  21. Visser L., Louw A. I. The importance of protein structure and conformation in the preparation of phospholipase-free cardiotoxin from snake venom. Biochim Biophys Acta. 1977 Mar 28;491(1):349–353. doi: 10.1016/0005-2795(77)90073-3. [DOI] [PubMed] [Google Scholar]
  22. Waldmann H., Lachmann P. J. The failure to show a necessary role for C3 in the in vitro antibody response. Eur J Immunol. 1975 Feb;5(2):185–193. doi: 10.1002/eji.1830050307. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES